New immune cells targeting CD70 and CLL1 for AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of immune cell (CAR-ITNK) that targets two proteins, CD70 and CLL1, on leukemia cells. It's for people with AML that has come back or not responded to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have AML that has returned or not improved after treatment.
- Your leukemia cells must have both CD70 and CLL1 proteins (confirmed by a test).
- Your liver, kidneys, lungs, and heart must be working well enough.
- You must agree to use birth control for at least 1 year after treatment (if applicable).
- You cannot have active infections, certain past therapies, or serious nervous system conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a therapy made from your own immune cells, engineered to target a marker called CLL-1 on leukemia cells, for people whose AML has come back or hasn't responded to standard treatments.
This trial tests a two-step treatment: first a targeted immune cell therapy (CLL1 CAR-T) to attack leukemia cells, followed by a stem cell transplant to rebuild healthy blood cells. It is for people with acute myeloid leukemia that has returned or not responded to previous chemotherapy.
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
This trial tests a new type of immune cell therapy (CAR-T) that targets three proteins (CLL1, CD33, NKG2D) on leukemia cells in patients with acute myeloid leukemia that has not responded to or come back after prior treatment.
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
This trial tests a type of immunotherapy called CAR-T cells that are made to target leukemia cells. The cells are designed to attack AML by recognizing several proteins on the cancer cells, and may be an option for patients who have not responded well to other treatments.
Hear when a new R/R AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.